Skip to main content
Terug
Watch Compare

Spero Therapeutics, Inc.

Datakwaliteit: 100%
SPRO
Nasdaq Manufacturing Chemicals
€ 2,79
▲ € 0,07 (2,57%)
Marktkapitalisatie: 161,52 M
Prijs
€ 2,79
Marktkapitalisatie
161,52 M
Dagbereik
€ 2,67 — € 2,79
52-Weeksbereik
€ 0,52 — € 3,22
Volume
355.015
Openen € 2,72
50D / 200D Gem.
€ 2,36
18,44% above
50D / 200D Gem.
€ 2,32
20,01% above

Quick Summary

Belangrijkste Punten

Revenue grew 38,31% annually over 5 years — strong growth
ROE of 28,90% indicates high profitability
Negative free cash flow of -12,62 M

Groei

Revenue Growth (5Y)
38,31%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)39,24%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
28,90%
Boven sectorgemiddelde (-53,47%)
ROIC13,97%
Net Margin12,83%
Op. Margin9,45%

Veiligheid

Debt / Equity
N/A
Current Ratio3,83
Interest CoverageN/A

Waardering

PE (TTM)
18,84
Boven sectorgemiddelde (-1,47)
P/B Ratio6,10
EV/EBITDA17,88
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E 18,8 -1,5
P/B 6,1 1,6
ROE % 28,9 -53,5
Net Margin % 12,8 -41,5
Rev Growth 5Y % 38,3 1,8
D/E — 0,3

ETFs Holding This Stock

BRSIX BRSIX
0,08% weight
BOSVX BOSVX
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 39,24% Revenue Growth (3Y) -19,77%
Earnings Growth (1Y) N/A Earnings Growth (3Y) -38,69%
Revenue Growth (5Y) 38,31% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 66,80 M Net Income (TTM) 8,57 M
ROE 28,90% ROA 14,74%
Gross Margin N/A Operating Margin 9,45%
Net Margin 12,83% Free Cash Flow (TTM) -12,62 M
ROIC 13,97% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3,83
Interest Coverage N/A Asset Turnover 1,15
Working Capital 38,67 M Tangible Book Value 26,49 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 18,84 Forward P/E N/A
P/B Ratio 6,10 P/S Ratio 2,42
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 17,88 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -7,82%
Market Cap 161,52 M Enterprise Value 112,90 M
Per Share
EPS (Diluted TTM) 0,15 Revenue / Share 1,15
FCF / Share -0,22 OCF / Share -0,22
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion -147,27%
SBC-Adj. FCF -18,10 M Growth Momentum 0,93

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 66,80 M 47,98 M 103,78 M 53,51 M 18,26 M
Net Income 8,57 M -68,57 M 22,81 M -46,42 M -89,80 M
EPS (Diluted) 0,15 -1,27 0,43 -1,23 —
Gross Profit — — — — —
Operating Income 6,31 M -73,36 M 21,48 M -42,20 M -87,97 M
EBITDA — — — — —
R&D Expenses 38,47 M 96,76 M 51,44 M 47,59 M 64,53 M
SG&A Expenses — — — — —
D&A 0,0 2.000,0 367.000,0 869.000,0 646.000,0
Interest Expense — — — — —
Income Tax 261.000,0 0,0 2,60 M 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 68,92 M 110,54 M 182,39 M 124,80 M 171,07 M
Total Liabilities 9,90 M 64,42 M 75,50 M 48,87 M 82,78 M
Shareholders' Equity 59,02 M 46,12 M 106,89 M 75,93 M 88,29 M
Total Debt — — — — —
Cash & Equivalents 40,27 M 52,89 M 76,33 M 109,11 M 112,58 M
Current Assets 67,29 M 107,28 M 131,21 M 113,57 M 157,87 M
Current Liabilities 8,87 M 49,07 M 37,15 M 21,65 M 18,67 M